Belfast pharmaceutical company Fusion Antibodies signs £ 1.3million deal with US biotech company

0


Fusion Antibodies has signed a deal with a US biotech company worth at least £ 1.3million ($ 1.83million) over the next two years.

The Belfast research-based pharmaceutical company said the contract would allow it to provide early-stage antibody discovery and engineering services to the anonymous partner.

It will use its RAMP technology platform, which helps accelerate antibody discovery where traditional discovery methods have failed.

Fusion Antibodies is a spin-off from Queens University Belfast and listed on the Alternative Investment Market of the London Stock Exchange.

“This contract is also a further demonstration of the expertise and capabilities of Fusion Antibodies,” said Dr. Julie Gormley, Senior Commercial Director. “Through the use of our own proprietary RAMPTM platform, we provide our client with the ability to drive the discovery of novel therapeutic antibodies against difficult targets where traditional discovery efforts have previously failed.

“We are delighted to be working with a team of passionate scientists to provide essential solutions regarding the research and development of several predetermined projects and as we continue to grow and invest in our technologies and our team, we hope to provide such support to many more customers around the world as our industry evolves over the next 10 to 20 years. “

The move follows Fusion Antibodies’ agreement with drug discovery company Eurofins Discovery in August, which will see the two companies working together to support biotherapeutic discovery.

“Under our new CEO, Dr. Richard Jones, Fusion Antibodies’ approach is to grow the business with an emphasis on utilizing the organization’s strong track record,” said James Fair, Chief Financial Officer of Fusion Anitbodies. “By showcasing the knowledge and expertise of our exceptional staff, as well as our premier proprietary platforms, we are in a privileged position to continue to win major long-term contracts like the one we announced today.” . We look forward to honoring the contract and continuing to collaborate with other such organizations. “


Leave A Reply

Your email address will not be published.